InvestSMART

Racura Oncology Ltd (ASX:RAC)

ALERT: Price-sensitive ASX Announcement for RAC
Current share price for RAC : $2.130 0.09 (4.41%)+
Announcement
Release
29 Jul 2026 9:04AM
Price at Release
$2.040
Full Release
download
Summary
Racura Oncology Ltd has announced the successful treatment of the first patient in its HARNESS-1 trial using RC220 in combination with osimertinib. The Safety Review Committee (SRC) confirmed no dose-limiting toxicities or treatment-related safety concerns in the initial cohort. However, the patient reported moderate colitis symptoms post-treatment, prompting the SRC to recommend treating an additional patient at the current dose level before escalating. The trial is designed to evaluate the safety and efficacy of RC220 for EGFR-mutant non-small cell lung cancer using an accelerated dose titration design. The next SRC review is expected in 6–8 weeks, and recruitment for the next patient is underway.
Key Points
  • First patient treated with RC220 and osimertinib in HARNESS-1 trial.
  • No dose-limiting toxicities identified; moderate colitis symptoms reported.
  • SRC recommends treating one additional patient before dose escalation.
  • Trial uses an accelerated dose titration design.
  • Next SRC review expected in 6–8 weeks.
  • Recruitment for the next patient is underway.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.